Dezapelisib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameDezapelisib
Drug Alias NameINCB-40093INCB-0400932K59L7G59M (UNII code)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitors
TargetsPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsLymphoma, B-CellHodgkin DiseaseLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesIncyte Corp
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLeukemia, B-Cell
Inactive IndicationsHodgkin Disease

Other Information

ATC CodeN/A
Related LinksN/A